A rising PSA after prostate cancer treatment is called biochemical recurrence. It is detected early — before any symptoms — which is precisely what regular PSA follow-up is designed to do. Early detection at this stage means salvage treatment is still highly effective.
You finished treatment for prostate cancer — surgery, radiation, or both. The follow-up PSA tests have been normal. Then one result comes back slightly higher than the last. Then another. Your urologist says this may be "biochemical recurrence."
The alarm you feel is completely understandable. A rising PSA after cancer treatment is concerning. But understanding what it means — and what it does not mean — is the first step to addressing it calmly and effectively.
1. What is biochemical recurrence?
Biochemical recurrence (BCR) means that PSA — the marker of prostate cancer activity — is rising after treatment that was intended to be curative. It is called "biochemical" because it is detected by a blood test, not by symptoms or scans. This is the earliest possible stage at which recurring cancer can be identified.
BCR is common: approximately 20–30% of men treated for prostate cancer will experience a rising PSA within 10 years of treatment. For many of these men, the PSA rise is slow, reflects a small amount of residual prostate tissue, and does not progress to clinically significant disease for years or decades.
Biochemical recurrence detected by PSA alone — without positive imaging — does not confirm that cancer has metastasised. The cancer may be localised (confined to the prostate bed or pelvic area) and still amenable to curative salvage treatment. This distinction is critical.
2. After surgery — PSA definitions
After complete surgical removal of the prostate (radical prostatectomy), the PSA should fall to undetectable levels — below 0.1 ng/mL — within 4–6 weeks. Any PSA produced is coming from cancer cells that were not removed.
BCR after prostatectomy is defined as: PSA reaching 0.2 ng/mL or above on two consecutive measurements.
3. After radiation — PSA definitions
After external beam radiation or brachytherapy, PSA does not immediately become undetectable. The prostate is treated but not removed — PSA continues to be produced by treated prostate tissue. PSA declines slowly over 12–18 months to a "nadir" (lowest point).
BCR after radiation is defined using the Phoenix criteria: PSA rising 2 ng/mL or more above the lowest PSA nadir achieved.
A temporary PSA increase called "PSA bounce" can occur 12–24 months after radiation — this is a benign phenomenon caused by prostate tissue inflammation and does not represent recurrence. Your urologist will distinguish between a bounce and true BCR based on the PSA pattern over time.
4. What a rising PSA actually means
Not all BCR is equal. Two key parameters predict the behaviour of the recurrence:
PSA doubling time (PSADT)
How quickly the PSA is doubling is the most important predictor of whether the recurrence will progress to metastatic disease. A PSA doubling time above 15 months is considered favourable — many men with this pattern will not develop symptomatic metastases for decades. A PSADT below 6 months indicates rapid growth and more aggressive disease requiring prompt attention.
Time to BCR
A PSA that rises within 12 months of treatment suggests the cancer was not fully controlled by local therapy. A BCR appearing 5–10 years after treatment suggests either a late local recurrence or very slow-growing systemic disease — a fundamentally different prognosis.
"My PSA is rising after surgery — the cancer is back and it's going to spread."
A slowly rising PSA, particularly with a long doubling time, may never progress to symptomatic disease. Even when treatment is needed, salvage radiation after prostatectomy has a 50–70% chance of achieving durable PSA control.
5. Investigating biochemical recurrence
When BCR is confirmed, the goal is to localise the recurrence — is it local (within the pelvis) or systemic (lymph nodes or bones)? This determines the treatment approach entirely.
PSMA PET-CT
The most sensitive investigation for BCR. Can detect the site of recurrence at PSA levels as low as 0.2–0.5 ng/mL — far below what conventional CT or bone scan can detect. Identifies local recurrence in the prostate bed, pelvic nodes, or distant metastases.
Conventional CT + bone scan
If PSMA PET is not available, conventional staging scans are done — but they often miss disease at low PSA levels. A negative CT and bone scan with a low, slowly rising PSA does not exclude local recurrence.
Multiparametric MRI (after surgery)
MRI of the prostate bed can identify local recurrence at the anastomosis site — where the urethra was rejoined to the bladder after prostatectomy. A visible nodule on mpMRI targets salvage radiation more precisely.
6. Treatment options for BCR
After surgery — salvage radiation
Salvage external beam radiation to the prostate bed is the primary treatment for BCR after prostatectomy. It is most effective when given at low PSA levels (below 0.5 ng/mL) and can achieve long-term PSA control — and likely cure — in approximately 50–70% of patients treated at this stage.
Hormone therapy (ADT) in combination
Adding short-course androgen deprivation therapy (testosterone suppression) to salvage radiation significantly improves outcomes for high-risk recurrences. The duration varies — 4 months to 2 years — based on clinical factors.
Metastasis-directed therapy
If PSMA PET shows oligometastatic disease (1–3 metastatic sites), stereotactic body radiation (SBRT) targeting each site can achieve durable disease control and delay the need for systemic hormone therapy.
Observation for slow BCR
For men with very slow PSA doubling time (>15 months) after prostatectomy, particularly if elderly or with significant comorbidities, close monitoring without immediate treatment is reasonable. Many such men will never require treatment during their lifetime.
- What is my PSA doubling time — and what does it suggest about the behaviour of the recurrence?
- Should I have a PSMA PET scan at this PSA level?
- Is the recurrence likely to be local or systemic based on the timing and pattern?
- If salvage radiation is recommended, should it include hormone therapy?
- If imaging shows a limited number of metastases, is SBRT an option?
- Can I be monitored without treatment given my PSA doubling time?
This article is for general patient education about biochemical recurrence after prostate cancer treatment. Management decisions require individual clinical assessment. Please discuss your specific PSA results and options with your urologist.